Cardio3 BioSciences Raises €7.2 Million
Cardio3 BioSciences, a Belgian developer of cell-based therapies for the treatment of cardiovascular diseases, has raised €7.2 million in Series B funding. Backers include Hunza Ventures, Life Science Research Partners and Grifols. In conjunction with the Series B funding, Cardio3 also secured €6.5 million in new cash advances from the Walloon Region General Directorate for Economy, Employment & Research.
19 January 2009•6 mins read
